The recent surge in capital into niche pharmaceutical companies, particularly those focusing on experimental therapies and complex drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the potential for revolutionary treatments and impressive returns is certain, the connected risks are also notable. Many of th